- |||||||||| Darzalex (daratumumab) / J&J
Daratumumab in Ittp: A Case Series () - Dec 7, 2024 - Abstract #ASH2024ASH_7606;
In relapsed patients, plasma exchange therapy is used, along with capalacizumab and either an increased dose of glucocorticoids or addition of another immunosuppressive therapy (cyclophosphamide, vincristine, cyclosporine, bortezomib, mycophenolate mofetil) (Farzana 2015)...We assessed the clinical and treatment course of two patients at our institution as well as platelet response, duration of response, and patient demographics.Results : Both patients documented in this case series presented with multiply relapsed iTTP after rituximab failure...As treatment with daratumumab becomes more favorable in this context, assessment of the demographic factors and clinical characteristics of patients and their response to the therapy will be important in determining which patient populations should receive daratumumab for treatment of their disease. We plan to conduct a meta-analysis of published literature of daratumumab in the relapse and refractory setting.
- |||||||||| alacizumab pegol (CDP 791) / UCB
DOUBLE TROUBLE: A RARE CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND PANCREATITIS IN THE ICU (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5222;
Physicians should remember that TTP is a serious hematologic emergency that may present with a wide array of systemic manifestations such as pancreatitis. Physicians should also maintain a high index of suspicion to promptly recognize and treat TTP to prevent mortality while also considering other pathologies that may be presenting concurrently.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, alacizumab pegol (CDP 791) / UCB
[VIRTUAL] A Novel Nanobody: Capalacizumab, in the Modern Era of TTP Treatment (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3063;
As with any novel treatments, further studies are indicated, especially those not funded by the drug manufacturer. Our patient did have a favorable response using capalacizumab in addition to steroids, rituximab, and plasmapheresis.
- |||||||||| Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, alacizumab pegol (CDP 791) / UCB
A Novel Nanobody: Capalacizumab, in the Modern Era of TTP Treatment (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) - Mar 15, 2020 - Abstract #ATS2020ATS_5430;
As with any novel treatments, further studies are indicated, especially those not funded by the drug manufacturer. Our patient did have a favorable response using capalacizumab in addition to steroids, rituximab, and plasmapheresis.
|
